↓ Skip to main content

Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?

Overview of attention for article published in Breast Cancer Research, January 2001
Altmetric Badge

Mentioned by

wikipedia
1 Wikipedia page

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?
Published in
Breast Cancer Research, January 2001
DOI 10.1186/bcr276
Pubmed ID
Authors

Suzanne A Eccles

Abstract

The first monoclonal antibodies (mAbs) approved for cancer therapy are now in Phase II and III trials, but the critical mechanism(s) determining efficacy and response in patients are still largely undefined. Both the direct antigen-binding (Fab) and constant (Fc) regions of mAbs can contribute to their biological activity. However, Clynes et al (Nat Med 2000, 6:443) recently suggested that the latter (at least in experimental models) might be the dominant component in vivo, triggering host responses to destroy cancer cells. Those workers showed that in mice lacking 'activation' Fc receptors (Fc(gamma)RI and Fc(gamma)RIII), anti-tumour effects of certain mAbs were significantly reduced. In contrast, mice deficient in the 'inhibitory' receptor Fc(gamma)RIIB responded with tumour growth inhibition and enhanced antibody-dependent cellular cytotoxicity (ADCC). These observations suggest that mAbs might be engineered for preferential binding to Fc(gamma)RIII to maximise therapeutic benefit. However, further work is needed to establish a definitive cause-effect relationship in experimental models that are more clinically relevant, to determine whether human Fc(gamma)R isoforms behave in a similar fashion, and to confirm that therapeutic mAbs and host cells can adequately access solid tumour deposits to mediate effective ADCC in situ. Finally, the 'cost-benefit' ratio of such modified macromolecules will need to be measured against mini-mAb constructs, antisense oligonucleotides, peptidomimetics and emerging drugs capable of inhibiting key tumour cell signalling pathways.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 3%
Belgium 1 3%
Unknown 34 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 22%
Student > Master 7 19%
Student > Bachelor 6 17%
Student > Ph. D. Student 5 14%
Student > Postgraduate 3 8%
Other 2 6%
Unknown 5 14%
Readers by discipline Count As %
Agricultural and Biological Sciences 13 36%
Biochemistry, Genetics and Molecular Biology 7 19%
Medicine and Dentistry 7 19%
Chemistry 2 6%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 0 0%
Unknown 6 17%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 October 2011.
All research outputs
#7,453,126
of 22,785,242 outputs
Outputs from Breast Cancer Research
#879
of 1,896 outputs
Outputs of similar age
#26,431
of 114,244 outputs
Outputs of similar age from Breast Cancer Research
#2
of 7 outputs
Altmetric has tracked 22,785,242 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,896 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 114,244 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.